At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 656 enrolled
Drug / intervention
NCX 470 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Multicenter, Masked, Parrallel-Group, Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 (3 Doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating NCX 470 and Latanoprost 0.005% for Glaucoma, Open-Angle and Hypertension, Ocular. Completed, enrolled 656 participants across 1 site.
Detailed Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Hypertension, Ocular
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedSep 2018
Primary CompletionAug 2019
TodayJul 2026
First PostedSep 5, 2018
Enrollment StartAug 1, 2018
Primary CompletionAug 23, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago
Interventions
NCX 470drug
NCX 470 Ophthalmic Solution
Latanoprost 0.005%drug
Latanoprost 0.005% Ophthalmic Solution